Author:
Haslbauer Ferdinand,Petzer Andreas,Safanda Martin,Tomova Antoaneta,Porubska Miriam,Bajory Zoltán,Niepel Daniela,Jaeger Christine,Bjorklof Katja,Kalinin Dmitry,Greil Richard
Publisher
Springer Science and Business Media LLC
Reference11 articles.
1. Coleman RE, Brown JE (2005) Monitoring response to treatment—the role of biochemical markers. In: Jasmin C, Coleman RE, Coia LR, Capanna R, Saillant G (eds) Textbook of bone metastases. John Wiley & Sons Ltd., Chichester, UK
2. Coleman RE (2004) Bisphosphonates: clinical experience. Oncologist 9(Suppl 4):14–27
3. Vogel CL, Yanagihara RH, Wood AJ, Schnell FM, Henderson C, Kaplan BH, Purdy MH, Orlowski R, Decker JL, Lacerna L, Hohneker JA (2004) Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy. Oncologist 9:687–695
4. Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning GA, Schulman KA (2005) The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 16:579–584
5. European Medicines Agency (2018) Xgeva summary of product characteristics. In: Book Xgeva summary of product characteristics. European Medicines Agency, City
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献